

ONLINE SUPPLEMENTARY CONTENT**Table SI - Accrual and results of clinical trial**

N	Code	Arm	Initial measure (Area cm ²)	Measure at 4 weeks	Measure at 4 month
				Area cm ² (% of reduction to/closed)	Area cm ² (% of reduction to/closed)
1	BST-01	CBPG	Withdrawn	n.a.	n.a.
2	BST-02	CBPG	0.98	0.55 (44%) [8 CBPG]	0.28 (71%)
3	BST-03	STD	0.42	healed at 3 weeks (V5; 100%)	0 (100%)
4	BST-04	STD	0.8	0.3 (62.5%)	0.6 (25%)
5	BST-05	CBPG	Withdrawn	n.a.	n.a.
6	BST-06	CBPG	Withdrawn	n.a.	n.a.
7	BST-07	STD	Withdrawn	n.a.	n.a.
8	BST-08	CBPG	0.25	healed at 3 weeks (V5; 100%) [5 CBPG]	0 (100%)
9	BST-09	STD	0.25	Infected at week 2 (V4)	
10	BST-10	CBPG	10.4	8.4 (20%) [8 CBPG]	0 (100%)
11	BST-11	STD	Withdrawn	n.a.	n.a.

CBPG: cord blood platelet gel; STD: standard treatment; n.a.: not applicable.

Table SII - Potential CBPC production based on banking activity

Year	No. of WCB units collected	No. (%) of units processed for stem cell bank	No. (%) of potential* units for CBPC
2014	8,031	1,317 (16%)	4,489 (56%)
2015	6,510	748 (11%)	3,621 (55%)
2016	4,973	580 (11%)	3,712 (74%)
2017	4,221	459 (11%)	3,111 (74%)
2018	3,397	333 (10%)	2,086 (62%)
Median	4,973	580 (11%)	3,621 (62%)

*CB units used for cryopreservation for HPC product and potential. CB units to prepare CBP product.

CBPC: cord blood platelet concentrates; WCB: whole cord blood

Table SIII - Costs incurred for CBPC manufacturing in BST

Item	Cost (€)
Consumables	20.2
Quality Controls	70.4
Labor	29.5
Facilities and maintenance	36
Total	156.1

CBPC: cord blood platelet concentrates.